Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial – Endpoints News October 13, 2023
G1 Therapeutics abandons PhIII colorectal cancer trial after disappointing overall response rates – Endpoints News February 13, 2023